Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial

Journal of Urology

Volumn 157, Issue 3, 1997, Pages 855-859

  Culine, S ^a,b   Theodore, C ^a   Terrier Lacombe, M J ^a   Droz, J P ^a,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE VAL D AURELLE   (France)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

germinoma; neoplasm metastasis; prognosis; testicular neoplasms

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ADULT; ARTICLE; CANCER RECURRENCE; CLINICAL TRIAL; DRUG EFFICACY; GERM CELL TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TESTIS TUMOR; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0031023230     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65063-8     Document Type: Article

References (17)

1. Einhorn L. H.: Treatment of testicular cancer: a new and improved model. J. Clin. Oncol., 8: 1777, 1990.
2. Samuels, M. L., Johnson, D. E. and Holoye, P. Y.: Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III testicular neoplasia. Cancer Chemother. Rep., part 1, 59: 563, 1975.
3. Einhorn, L. H. and Donohue, J.: Cis-diaminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med., 87: 293, 1977.
4. Williams, S. D., Birch, R., Einhorn, L. H., Irwin, L., Greco, F. A. and Loehrer, P. J.: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide N. Engl. J. Med., 316: 1435, 1987.
5. Bosl, G. J., Gluckman, R., Geller, N. L., Golbey, R. B., Whitmore, W. F., Jr., Herr, H., Sogani, P., Morse, M., Martini, N., Bains, M. and McCormack, P.: VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. J. Clin. Oncol., 4: 1493, 1986.
6. Einhorn, L. H., Williams, S. D., Loehrer, P. J., Birch, R., Drasga, R , Omura, G. and Greco, F. A.: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J. Clin. Oncol., 7: 387, 1989.
7. Bosl G. J., Geller, N. L., Bajorin, D., Leitner, S. P., Yagoda, A., Golbey R. B., Scher, H., Vogelzang, N. J., Auman, J., Carey, R., Fair, W. R., Herr, H., Morse, M., Sogani, P. and Whitmore, W.: A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J. Clin. Oncol., 6: 1231, 1988.
8. Culine, S., Mahjoubi, M., Philippot, I. and Droz, J. P.: Treatment of good-risk disseminated non-seminomatous germ cell tumours: the less bleomycin, the more cisplatin? Letter to the Editor. Eur. J. Cancer, 27: 1715, 1991.
9. Droz, J. P. Kramar, A., Ghosn, M., Piot, G., Rey, A., Theodore, C., Wibault, P., Court, B. H., Perrin, J. L., Travagli, J. P., Bellet, D., Caillaud, J. M., Pico, J. L. and Hayat, M.: Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis. Cancer, 62: 564, 1988.
10. Birch, R., Williams, S., Cone, A., Einhorn, L., Roark, P., Turner, S. and Greco, F. A.: Prognostic factors for favorable outcome in disseminated germ cell tumors. J. Clin. Oncol., 4: 400, 1986.
11. Mead, G. M.: International consensus prognostic classification for metastatic germ cell tumours treated with platinum based chemotherapy: final report of the International Germ Cell Cancer Collaborative Group. Proc. Amer. Soc. Clin. Oncol., 14: 235, 1995.
12. Bosl, G. J., Geller, N. L., Cirrincione, C., Vogelzang, N. J., Kennedy, B. J., Whitmore, W. F., Jr., Vugrin, D., Scher, H., Nisselbaum, J. and Golbey, R. B.: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res., 43: 3403, 1983.
13. Droz, J. P., Kramar, A. and Rey, A.: Prognostic factors in metastatic disease. Sem. Oncol., 19: 181, 1992.
14. Peckham, M. J., Horwich, A., Blackmore, C. and Hendry, W. F.: Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma. Cancer Treat. Rep., 69: 483, 1985.
15. Levi J. A., Raghavan, D., Harvey, V., Thompson, D., Sandeman, T., Gill, G., Stuart-Harris, R., Snyder, R., Byrne, M., Kerestes, Z. and Margrie, S.: The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. J. Clin. Oncol., 11: 1300, 1993.
16. Bosl, G. J.: Management of metastatic germ cell tumours: toxicity reduction and the use of bleomycin. In: Testicular Cancer -Clinical Investigation and Management. Edited by A. Horwich. New York: Chapman & Hall, pp. 205-212, 1991.
17. Loehrer, P. J., Sr., Johnson, D., Elson, P., Einhorn, L. H. and Trump, D.: Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol., 13: 470, 1995.